While molecular targeted therapies, including EGFR and ALK inhibitors, have transformed first-line treatment, their effectiveness in advanced NSCLC is frequently constrained by acquired resistance and tumor heterogeneity (Wang et al. 2023). Here, ALK is linked to neoplasm.